Seven consecutive years of wins since first contract in 2020
Plans to extend trust to the private-sector market

Celltrion's breast and stomach cancer treatment Herzuma (active ingredient: trastuzumab) has won Brazil's federal government tender for the seventh consecutive year, securing a foothold in Latin America's largest pharmaceutical market. By securing a supply volume that accounts for most of Brazil's public-sector market, the company has also cemented Herzuma's position as the country's most-prescribed product in its category.

Product image of Celltrion's breast and gastric cancer treatment Herzuma (active ingredient: trastuzumab). Celltrion

Product image of Celltrion's breast and gastric cancer treatment Herzuma (active ingredient: trastuzumab). Celltrion

View original image

On November 17, Celltrion said its Brazilian subsidiary had won the federal government tender and would be the sole supplier of approximately 1 million vials of Herzuma through the end of 2027. Herzuma has won the tender every year for seven consecutive years, beginning with its first contract in 2020, the year after its launch. The volume awarded in this tender represents approximately 80% of Brazil's public-sector trastuzumab market.


Brazil's pharmaceutical market is divided into a public-sector market overseen by the federal government and a private-sector market in which hospitals select products independently. The two markets account for approximately 80% and 20%, respectively. Celltrion has continued to win contracts in the public-sector market, a key channel, through a direct-sales strategy tailored to local conditions. Since major medical professionals in Brazil often work at both public and private healthcare institutions, the company plans to leverage the trust it has built in the public-sector market to expand in the private-sector market.


Celltrion's reliable supply capacity is cited as a key factor behind the contract win. The company has the production capacity to supply up to 1 million vials to a single country without disruption, and this is believed to have worked in its favor in the tender. Herzuma currently leads prescriptions in Brazil, with an approximately 50% market share, ahead of the original product and competing products, according to IQVIA.


Celltrion plans to expand its presence in Brazil with new products. Omlyclo (active ingredient: omalizumab), a treatment for chronic spontaneous urticaria launched late last year, won a tender from the state government of Santa Catarina and has also reached an approximately 26% share of the private-sector market. At the end of this year, the company plans to launch Eydenzelt (active ingredient: aflibercept), a treatment for eye diseases, and Aptozma (active ingredient: tocilizumab), a treatment for autoimmune diseases, expanding its business into the ophthalmology field.



"Our long-standing success in Brazil is the result of a tailored sales strategy, a robust local network, and strong trust in our products working together," said Kang Gyeongdu, Celltrion's regional head for Latin America. "We will build on our direct-sales competitiveness established with our existing products by adding follow-on products, expand our influence in Brazil, and use that as a springboard to create new growth opportunities throughout Latin America."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing